Taj Worldwide | Taj Group | Media | Career | FAQs | Feedback | contact us
 
Taj Logo
Lobivir especially Products
 
Quality Medicines Api Generic Manufacturing For Doctors Brands Newsroom
 

Lobivir Taj Products

 
HOME >> PRODUCTS >> Taj Products >> Lobivir
Taj  ALL Products View Products According to Category


Each film-coated tablet contains
Composition

Lamivudine .....................................................................100 mg

Indications
Lobivir HBV is indicated for the treatment of chronic Hepatitis B and evidence of hepatitis B virus (HBV) replication in patients with decompensated liver disease or active inflammation and/or fibrosis.

Description
Lamivudine (ß-L-2',3'-dideoxy-3'-thiacytidine), one of the dideoxycytidine (ddC) analogue NRTIs, is the first nucleoside analogue approved to treat chronic HBV infection and has been shown to benefit various categories of patients. These include HBe-positive and -negative patients, non-responders to interferon-{alpha} therapy, and patients with decompensated cirrhosis.

Lamivudine’s D-isomer is less active against HBV replication and more cytotoxic than the L-isomer. Both the D- and L-isomers of 2',3'-dideoxy- 3'-thiauridine were found to be inactive against HBV replication, and the susceptibility of the thiacytidine stereoisomers to cytidine and/or deoxycytidine deaminase was suspected to be the reason. In fact, the racemic mixture and the D-isomer of 2',3'-dideoxy-3'-thiacytidine were deaminated with partially purified human deaminase and were found to be processed to the

D-isomer of the thiauridine, while lamivudine and ddC were not. Despite the intracellular stability of its cytosine base, ddC was less effective than lamivudine in a cell culture system. Until recently, it was thought that the potency of lamivudine reflected the higher incorporation efficiency into newly synthesized DNA by the viral DNA polymerase. Lamivudine and ddC are phosphorylated to their triphosphates and then the triphosphates act as chain terminators during viral and cellular DNA synthesis.

CONTRA-INDICATIONS
EPIVIR Tablets and Oral Solution are contraindicated in patients with previously demonstrated clinically significant hypersensitivity to any of the components of the products.

Dosage
The recommended dosage of Lobivir HBV is 100 mg once daily or as per the physician’s advice.

Presentations
10 tablets

 

 


Note : This product information is intended only for residents of the India. Taj Pharmaceuticals Limited,  medicines help to treat and prevent a range of conditions—from the most common to the most challenging—for people around the world.

Information for Health Care Professionals

*** Please consult local Prescribing Information for any product before use. This website is an international information resource for healthcare professionals with an interest in disease management. This website is not intended to replace the advice of a qualified healthcare professional. Above brand is a trademark of the Taj group of companies (Taj Pharmaceuticals Limited)






 

Lobivir ® Logo



Lobivir









 

 

 



 

              
 Print page   Send by mail



 

   
   
PRODUCTS
 
 
   
   
   
  india flag
  The Taj Pharmaceuticals Limited (Taj Group) has operations in every major international market
    AFRICA
  ASIA PACIFIC
  EUROPE
  MIDDLE EAST
  THAILAND
  BANGLADESH
  NORTH AMERICA
  SOUTH AMERICA
  RUSSIA
  NEWZELAND
  UNITED KINGDOM
 

`  

 

 

 
 www.tajpharma.com

   

 

About Taj

Company

Products Diseases Health Divisions Media R & D Sustainability
Figure & Reports Investors

Countries

Brochure E-mail us Export & Import
Vacancies | C & F Agency | Distributor | Group Companies | History | Enquire Form | Countries | Pharma Technology
 Contact | Sitemap | User Terms and Conditions | Privacy and Cookie Statement